Axon Enterprise, Inc. (NASDAQ:AXON) Receives $412.42 Consensus Target Price from Analysts

Axon Enterprise, Inc. (NASDAQ:AXON) has received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $427.83.

A number of research firms recently weighed in on AXON. Jefferies Financial Group initiated coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target for the company. Craig Hallum boosted their target price on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Bank of America initiated coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target for the company. Barclays increased their price objective on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Needham & Company LLC upped their price target on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock opened at $601.29 on Monday. The stock has a market capitalization of $45.85 billion, a price-to-earnings ratio of 155.37, a P/E/G ratio of 14.95 and a beta of 0.94. The firm’s 50-day moving average price is $428.90 and its two-hundred day moving average price is $353.54. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. Axon Enterprise has a 1-year low of $220.51 and a 1-year high of $624.84.

Insider Transactions at Axon Enterprise

In related news, President Joshua Isner sold 20,000 shares of Axon Enterprise stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $606.15, for a total transaction of $12,123,000.00. Following the transaction, the president now owns 208,166 shares of the company’s stock, valued at $126,179,820.90. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $606.15, for a total value of $12,123,000.00. Following the completion of the transaction, the president now directly owns 208,166 shares of the company’s stock, valued at approximately $126,179,820.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brittany Bagley sold 4,338 shares of Axon Enterprise stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $378.95, for a total value of $1,643,885.10. Following the transaction, the chief financial officer now owns 98,825 shares in the company, valued at $37,449,733.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 389,172 shares of company stock worth $148,393,842. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Axon Enterprise

A number of hedge funds and other institutional investors have recently made changes to their positions in AXON. Blue Trust Inc. boosted its position in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after buying an additional 79 shares during the period. Quent Capital LLC lifted its position in shares of Axon Enterprise by 1,875.0% in the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 75 shares in the last quarter. Brooklyn Investment Group bought a new position in Axon Enterprise in the third quarter valued at $41,000. Asset Dedication LLC acquired a new stake in Axon Enterprise in the 2nd quarter valued at $47,000. Finally, Planning Capital Management Corp boosted its stake in shares of Axon Enterprise by 83.3% during the 3rd quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock worth $48,000 after buying an additional 55 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.